Immunomedics Inc. ($IMMU) stock is trading low after gaining over 10% in its previous trading session. The stock had reacted to positive information about its drug candidate IMMU-140. The company reported that the investigational product from its antibody-drug conjugate (ADC) program, showed a significant antitumor effect without any undue toxicity in four hematopoietic tumors in preclinical studies.

The goal of this preclinical study was to determine if SN-38, a drug which is not commonly used in liquid malignancies, would prove to be an effective and safe therapeutic when targeted with the IMMU-114 antibody, which could then improve the antitumor activity of IMMU-114.

The company also recently offered other updates about antibody-drug conjugate program. Immunomedics reported that it has awarded a US patent for protecting the use of sacituzumab govitecan (IMMU-132), the Company’s lead antibody-drug conjugate (ADC), for the treatment of patients with Trop-2-positive cancers.

Phase 2 clinical study has provided encouraging results. Consequently, the company is mulling the option of expanding the ADC program to include liquid tumors.

Immunomedics is a clinical-stage biopharmaceutical company. It is engaged in developing targeted treatment of autoimmune disorders, cancer and other ailments. Immunomedics Inc. stock has gained 11% this year so far and is likely to boost further owing to latest developments.